MedTrace Logo

Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis

NCT07052097 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2026-02-10

No results posted yet for this study

Summary

To evaluate TQC2938 injection in all patients receiving background treatment with azelastine fluticasone nasal spray. The efficacy, safety and immunogenicity of the injection in patients with seasonal allergic rhinitis compared with placebo are expected to include 136 patients.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

DRUG

TQC2938 injection

TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.

DRUG

TQC2938 Placebo

TQC2938 placebo, 4 weeks as a treatment cycle.

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-31
Primary Completion
2025-09-12
Completion
2025-11-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07052097 on ClinicalTrials.gov